Benefits of tiotropium/olodaterol compared with tiotropium in patients with COPD receiving only LAMA at baseline: pooled analysis of 4 clinical trials

R. Buhl (Mainz, Germany), D. Singh (Manchester, United Kingdom), A. De La Hoz (Ingelheim am Rhein, Germany), F. Voß (Ingelheim am Rhein, Germany), G. Ferguson (Farmington Hills, United States of America)

Source: International Congress 2019 – COPD clinical studies: bronchodilators, corticosteroids and more
Session: COPD clinical studies: bronchodilators, corticosteroids and more
Session type: Poster Discussion
Number: 3382

Congress or journal article abstractE-poster

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
R. Buhl (Mainz, Germany), D. Singh (Manchester, United Kingdom), A. De La Hoz (Ingelheim am Rhein, Germany), F. Voß (Ingelheim am Rhein, Germany), G. Ferguson (Farmington Hills, United States of America). Benefits of tiotropium/olodaterol compared with tiotropium in patients with COPD receiving only LAMA at baseline: pooled analysis of 4 clinical trials. 3382

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you: